A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

Patient Inclusion Criteria Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study: * Histologically or cytologically confirmed metastatic or unresectable solid tumor. * Has failed treatment with all standard therapies for their malignancy. * Adequate Karnofsky Performance Status. * An expected survival of at least 3 months. * Adequate organ and bone marrow function. * Signed informed consent form for study participation prior to screening. Patient Exclusion Criteria Patients presenting with any of the following will be excluded in the study: * Clinically significant disease as defined by the protocol. * Surgical therapy or other therapies within period as defined by the protocol. * Any condition that will interfere with compliance with the protocol as determined by investigator.